Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization
Latest Information Update: 17 May 2022
At a glance
- Drugs Losartan (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- 12 Feb 2021 Status changed from active, no longer recruiting to completed.
- 13 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2020 Planned number of patients changed from 516 to 580.
Most Recent Events
Trial Overview
Purpose
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
Primary Endpoints
Percentage of Participants Admitted to the Hospital
description: Outcome reported as the percentage of participants per arm admitted to inpatient hospital care due to COVID-19-related disease within 15 days of randomization.
Currently, there is a pre-planned pooled analysis with a national trial network under development.
time_frame: 15 days
Other Endpoints
Change in PROMIS Dyspnea Scale
description: The PROMIS dyspnea scale consists of 4 subscales. 3 (1. general shortness of breath, 2. intensity, and 3. Frequency) are scored from 0 (no symptoms) to 10 (most severe). The 4th subscale is scored from 0-4 in response to the question "I've been short of breath" with 0 representing none and 4 the most severe, for a total range of 0-34. Results are difference between enrollment and day 10. There are no units.
time_frame: 10 days
Change in SF-12 Physical Composite Score
description: The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Physical score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The 33-item Severity bank assesses the severity of difficulty breathing during various specific activities (the same 33 activities assessed in Dyspnea Functional Limitations). Each activity is rated in terms of degree of dyspnea (0 = no shortness of breath, 1 = mildly short of breath, 2 = moderately short of breath, 3 = severely short of breath) while engaging in the activity over the past 7 days. Total scores range from 0 to 99 with higher scores reflecting greater levels of dyspnea during daily activity.
time_frame: 10 days
Change in SF-12 Mental Composite Score
description: The SF-12 is a self-reported validated outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12 question survey which is then scored by a clinician or researcher. Mental composite score is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
time_frame: 10 days
Daily Maximum Temperature
description: Participants will report their maximum daily oral temperature to the study team. Outcome is reported as the mean maximum daily body temperature (in degrees Celsius) over 10 days.
time_frame: 10 days
Count of Participants With an Emergency Department or Clinic Presentation
description: Outcome is reported as the mean number of emergency department and clinic presentations combined per participant in each arm.
time_frame: 28 days
Disease Severity Rating Day 15
description: Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
time_frame: 15 days
Change in Viral Load by Nasopharyngeal Swab at Day 9
description: Viral load is measured as number of viral genetic copies per mL.
time_frame: 9 days
Change in Viral Load by Nasopharyngeal Swab at Day 15
description: Viral load is measured as number of viral genetic copies per mL.
time_frame: 15 days
Percentage of Patients Admitted to the Intensive Care Unit Within 15 Days
description: Outcome reported as the percent of participants in each arm who require ICU admission by day 15 following randomization.
time_frame: 15 days
Need for Oxygen Therapy at 15 Days
description: Outcome reported as the percent of participants in each arm who require oxygen therapy by day 15 following randomization.
time_frame: 15 days [1]
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID-19 respiratory infection | treatment | - |
Subjects
- Subject Type patients
-
Number
Planned: 580
Actual: 117
- Sex male & female
- Age Group ≥ 18 years; adult
Patient Inclusion Criteria
- Positive laboratory test for COVID-19 based on local laboratory standard - Age greater than or equal to 18 years of age - One of the following: Upper respiratory symptoms (cough, rhinorrhea) or fever (>101.5) or loss of taste / smell
Patient Exclusion Criteria
- Randomization > 72 hours of meeting inclusion criteria - Randomization > 7 days of symptom onset - Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB) - Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to angioedema - Pregnant or breastfeeding women - Females able to have children not currently taking a protocol allowed version of contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate/Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives with verbalized commitment to taking daily throughout the study, condom use or abstinence during the study. All participants of child bearing potential enrolled in this fashion will be informed of the teratogenic risks. - Patient reported history or electronic medical record history of kidney disease, defined as: 1. Any history of dialysis 2. History of chronic kidney disease stage IV 3. Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 (must be have been measured within 1 month of enrollment) 4. Other kidney disease that in the opinion of the investigator, would affect losartan clearance - Patient reported dehydration and significantly decreased urine output in the past 72 hours - Most recent systolic blood pressure prior to enrollment <110 mmHg - Patient reported history or electronic medical record history of severe liver disease, defined as: 1. Cirrhosis 2. History of hepatitis B or C 3. Other liver disease that in the opinion of the investigator, would affect losartan clearance 4. Documented AST or ALT > 3 times the upper limit of normal within 3 months of randomization (if available in electronic medical record) - Potassium >5.0 mmol/L (must have been measured within 1 month) of enrollment - Concurrent treatment with aliskiren - Inability to obtain informed consent - Enrollment in another blinded randomized clinical trial for COVID
Trial Details
Identifiers
Identifier | Owner |
---|---|
NCT04311177 | ClinicalTrials.gov: US National Institutes of Health |
SURG2020-28683 | - |
Trial Dates
-
Initiation Dates
Planned : 02 Apr 2020
Actual : 09 Apr 2020
-
Primary Completion Dates
Planned : 01 Apr 2021
Actual : 01 Feb 2021
-
End Dates
Planned : 01 Apr 2021
Actual : 01 Feb 2021
Other Details
- Design double-blind; multicentre; parallel; prospective; randomised
- Phase of Trial Phase II
- Location USA
- Focus Therapeutic Use
Interventions
Drugs | Route | Formulation |
---|---|---|
LosartanPrimary Drug | Oral | Tablet |
Losartan
Participants in this arm will receive the study drug, Losartan.
Drug: Losartan (Losartan; 25 mg daily; oral administration) Other Name: Cozaar
Placebo
Participants in this arm will receive a placebo treatment.
Other: Placebo (Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration)
Trial Centres
Investigators
Investigator | Centre Name | Trial Centre Country |
---|---|---|
Christopher Tignanelli, MD
612-625-7911
show details
ctignane@umn.edu |
University of Minnesota | USA |
David Wacker, MD | University of Minnesota | USA |
Jeffrey Chipman, MD | M Health Fairview University of Minnesota Medical Center | USA |
Michael Puskarich, MD, MS
612-626-6911
show details
mike-em@umn.edu |
University of Minnesota | USA |
Michelle Biros, MD, MS | University of Minnesota | USA |
Nicholas Ingraham, MD | University of Minnesota | USA |
Ron Reikoff, MD | M Health Fairview University of Minnesota Medical Center | USA |
Timothy Schacker, MD | University of Minnesota | USA |
Centres
Centre Name | Location | Trial Centre Country |
---|---|---|
Hennepin County Medical Center | Minneapolis, Minnesota | USA |
M Health Fairview University of Minnesota Medical Center | Minneapolis, Minnesota | USA |
Mayo Clinic Health System | Rochester, Minnesota | USA |
The Minnesota Foundation |
-
|
-
|
University of Minnesota |
-
|
-
|
University of Minnesota | Minneapolis, Minnesota | USA |
Trial History
Event Date | Event Type | Comment |
---|---|---|
17 May 2022 | Other trial event | Last checked against ClinicalTrials.gov record. Updated 17 May 2022 |
12 Feb 2021 | Status change - completed | Status changed from active, no longer recruiting to completed. Updated 16 Feb 2021 |
13 Nov 2020 | Status change - active, no longer recruiting | Status changed from recruiting to active, no longer recruiting. Updated 18 Nov 2020 |
09 Apr 2020 | Other trial event | Planned number of patients changed from 516 to 580. Updated 14 Apr 2020 |
09 Apr 2020 | Status change - recruiting | Status changed from not yet recruiting to recruiting. Updated 14 Apr 2020 |
01 Apr 2020 | Other trial event | Planned initiation date changed from 16 Mar 2020 to 2 Apr 2020. Updated 06 Apr 2020 |
19 Mar 2020 | Other trial event | Planned number of patients changed from 478 to 516. Updated 26 Mar 2020 |
18 Mar 2020 | New trial record | New trial record Updated 18 Mar 2020 |
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG